Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells

Cancer Gene Therapy

Volumn 11, Issue 2, 2004, Pages 109-120

  Adwan, Hassan ^a   Bäuerle, Tobias J ^a   Berger, Martin R ^a  

^a Unit of Toxicology and Chemotherapy   (Germany)

Author keywords

Antisense oligonucleotides; Bone sialoprotein; Colony formation; MDA MB 231; Metastasis; Osteopontin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BONE SIALOPROTEIN II; CALCIUM BINDING PROTEIN; ERUCIC ACID; ERUCYLPHOSPHO N,N,N TRIMETHYLPROPANOLAMINE; GLYCOPROTEIN; OSTEONECTIN; OSTEOPONTIN; PROPANOLAMINE DERIVATIVE; SIALOPROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER STAGING; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CRYSTALLIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; RECEPTOR DOWN REGULATION; WOUND HEALING;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; GENE THERAPY; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDES, ANTISENSE; OSTEONECTIN; OSTEOPONTIN; PHOSPHORYLCHOLINE; PROPANOLAMINES; RATS; RATS, NUDE; SIALOGLYCOPROTEINS; TUMOR STEM CELL ASSAY;

ANIMALIA;

EID: 0942279599     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700659     Document Type: Article

References (54)

1. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-521.
2. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002;62:3417-3427.
3. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001;6:419-427.
4. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein 1 (osteopontin, 2ar) is a consequence of neoplastic transformation. Anticancer Res. 1989;9:1291-1299.
5. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 1985;232:715-724.
6. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol. 1993;13:225-246.
7. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000;19:615-622.
8. Rosol TJ. Pathogenesis of bone metastases: role of tumor-related proteins. J Bone Miner Res. 2000;15:844-850.
9. Fisher LW, Torchia DA. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280:460-465.
10. Diel IJ, Solomayer EF, Seibel MJ, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res. 1999;5:3914-3919.
11. Sharp JA, Sung V, Slavin J, Thompson EW, Henderson MA. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest. 1999;79:869-877.
12. Waltregny D, Bellahcene A, Van Riet I, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst. 1998;90:1000-1008.
13. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7:4060-4066.
14. Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, Armbruster FP. Improved purification of human bone sialoprotein and development of a homologous radio-immunoassay. Clin Chem. 1997;43:2076-2082.
15. Castronovo V, Bellahcene A. Evidence that breast cancer associated microcalcifications are mineralized malignant cells. Int J Oncol. 1998;12:305-308.
16. Porte H, Chastre E, Prevot S, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer. 1995;64:70-75.
17. Yamanaka M, Kanda K, Li NC, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol. 2001;166:2495-2499.
18. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999;59:4453-4457.
19. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001;19:816-827.
20. Bradshaw AD, Reed MJ, Sage EH. SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem. 2002;50:1-10.
21. Yan Q, Sage EH, SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 1999;47:1495-1506.
22. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science. 1989;244:48-52.
23. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 1984;12:387-395.
24. Senger M, Glatting KH, Ritter O, Suhai S. X-HUSAR, an X-based graphical interface for the analysis of genomic sequences. Comput Method Programs Biomed. 1995;46:131-141.
25. Dunn OJ. Multiple comparison using rank sums. Technometrics. 1964;6:241-252.
26. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93-141.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
28. Papagerakis P, Berdal A, Mesbah M, et al. Investigation of osteocalcin, osteonectin, and dentin sialophosphoprotein in developing human teeth. Bone. 2002;30:377-385.
29. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723-749.
30. Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 1994;54:2823-2826.
31. Arafat HA, Wein AJ, Chacko S. Osteopontin gene expression and immunolocalization in the rabbit urinary tract. J Urol. 2002;167:746-752.
32. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001;171:215-222.
33. Ibrahim T, Leong I, Sanchez-Sweatman O, et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metast. 2000;18:253-260.
34. Kim YW, Park YK, Lee J, Ko SW, Yang MH. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci. 1998;13:652-657.
35. Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the alpha4betal integrin-osteopontin interaction. Exp Cell Res. 2000;258:342-351.
36. Smith LL, Giachelli CM. Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res. 1998;242:351-360.
37. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61-85.
38. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H′s cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem. 2002;277:13700-13708.
39. Yan Q, Clark JI, Wight TN, Sage EH. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J Cell Sci. 2002;115:2747-2756.
40. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene. 2002;21:7077-7091.
41. TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98:1544-1549.
42. Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res. 1999;27:4328-4334.
43. Scherr M, Rossi JJ, Sczakiel G, Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res. 2000;28:2455-2461.
44. Lehmann MJ, Patzel V, Sczakiel G. Theoretical design of antisense genes with statistically increased efficacy. Nucleic Acids Res. 2000;28:2597-2604.
45. Branch AD. A good antisense molecule is hard to find. Trends Biochem Biocheni Sci. 1998;23:45-50.
46. Mergny JL, Duval-Valentin G, Nguyen CH, et al. Triple helix-specific ligands. Science. 1992;256:1681-1684.
47. Dennis JU, Dean NM, Bennett CF, Griffith JW, Lang CM, Welch DR. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett. 1998;128:65-70.
48. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem. 2002;85:728-736.
49. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed N1H 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 1994;54:832-837.
50. Su L, Mukherjee AB, Mukherjee BB. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene. 1995;10:2163-2169.
51. Gardner HA, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene. 1994;9:2321-2326.
52. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001Q1;98:49-56.
53. Baker EA, Vaughn MV, Haviland DL. Choices in transfection methodologies: transfection efficiency should not be the sole criterion. Focus. 2000Q2;22:31-33.
54. Nemoto H, Rittling SR, Yoshitake H, et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res. 2001Q3;16:652-659.